DOCSLIB.ORG

Company History Page 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Company History Page 1 Company_History LISTING OF COMPANIES IN 52‐WEEK (DAILY FORMAT) COMPANY TICKER TYPE 1347 PPTY INS HLDGS INC PIH EQUITY 180 DEGREE CAP CORP TURN EQUITY 1ST SOURCE CORPORATION SRCE EQUITY 21VIANET GROUP INC VNET EQUITY 2U INC TWOU EQUITY 3‐D SYS CORP DEL DDD EQUITY 3M COMPANY MMM EQUITY 51JOB INC JOBS EQUITY 58 COM INC WUBA EQUITY 8POINT3 ENERGY PARTNERS LP CAFD EQUITY 8X8 INCORPORATED EGHT EQUITY A10 NETWORKS INC ATEN EQUITY AAON INC AAON EQUITY AAR CORPORATION AIR EQUITY AARON'S, INC AAN EQUITY AASTROM BIOSCIENCES INC VCEL EQUITY ABAXIS INC ABAX EQUITY ABB LTD ABB EQUITY ABBOTT LABORATORIES ABT EQUITY ABBVIE INC ABBV EQUITY ABERCROMBIE & FITCH CO ANF EQUITY ABIOMED INC ABMD EQUITY ABM INDUSTRIES INCORPORATED ABM EQUITY ABRAXAS PETE CORP AXAS EQUITY ACACIA COMMUNICATIONS INC ACIA EQUITY ACACIA RESH CORP ACTG EQUITY ACADIA PHARMACEUTICALS INC ACAD EQUITY ACADIA REALTY TRUST AKR EQUITY ACCELERON PHARMA INC XLRN EQUITY ACCENTURE PLC IRELAND ACN EQUITY ACCO BRANDS CORP ACCO EQUITY ACCURAY INC ARAY EQUITY ACELRX PHARMACEUTICALS INC ACRX EQUITY ACETO CORPORATION ACET EQUITY ACHAOGEN INC AKAO EQUITY ACHILLION PHARMACEUTICALS IN ACHN EQUITY ACI WORLDWIDE INC ACIW EQUITY ACLARIS THERAPEUTICS INC ACRS EQUITY ACME UNITED CORPORATION ACU EQUITY ACORDA THERAPEUTICS INC ACOR EQUITY ACORN INTL INC ATV EQUITY ACTIVISION BLIZZARD INCORPORATED ATVI EQUITY ACTUA CORP ACTA EQUITY ACTUANT CORP ATU EQUITY ACUITY BRANDS INC AYI EQUITY ACUSHNET HOLDINGS CORP GOLF EQUITY ACXIOM CORP ACXM EQUITY ADAMAS PHARMACEUTICALS INC ADMS EQUITY ADAMS RESOURCES & ENERGY INCORPORATED AE EQUITY ADAPTIMMUNE THERAPEUTICS PLC ADAP EQUITY ADCARE HEALTH SYSTEMS INC ADK EQUITY ADDUS HOMECARE CORP ADUS EQUITY Page 1 Company_History ADDVANTAGE TECHNOLOGIES GROUP INC. AEY EQUITY ADECOAGRO S A AGRO EQUITY ADESTO TECHNOLOGIES CORP IOTS EQUITY ADIENT PLC ADNT EQUITY ADOBE SYSTEMS INC ADBE EQUITY ADTRAN INC ADTN EQUITY ADURO BIOTECH INC ADRO EQUITY ADVANCE AUTO PARTS INC AAP EQUITY ADVANCED ACCELERATOR APPLIC AAAP EQUITY ADVANCED DRAIN SYS INC DEL WMS EQUITY ADVANCED ENERGY INDS AEIS EQUITY ADVANCED MICRO DEVICES INC AMD EQUITY ADVANCED SEMICONDUCTOR ENGR ASX EQUITY ADVANSIX INC ASIX EQUITY ADVANTAGE OIL & GAS LTD AAV EQUITY ADVERUM BIOTECHNOLOGIES INC ADVM EQUITY ADVISORY BOARD COMPANY (THE) ABCO EQUITY AECOM ACM EQUITY AEGEAN MARINE PETROLEUM NETW ANW EQUITY AEGION CORP AEGN EQUITY AEGON N V ADR AEG EQUITY AEHR TEST SYSTEMS AEHR EQUITY AERCAP HOLDINGS NV AER EQUITY AERIE PHARMACEUTICALS INC AERI EQUITY AEROCENTURY CORP ACY EQUITY AEROHIVE NETWORKS INC HIVE EQUITY AEROJET ROCKETDYNE HOLDINGS, INC. AJRD EQUITY AEROVIRONMENT INC AVAV EQUITY AES CORP AES EQUITY AETERNA ZENTARIS INC AEZS EQUITY AETNA INC. AET EQUITY AEVI GENOMIC MEDICINE INC GNMX EQUITY AFFILIATED MANAGERS GROUP AMG EQUITY AFLAC INC AFL EQUITY AG MTG INVT TR INC MITT EQUITY AGCO CORP AGCO EQUITY AGENUS INC AGEN EQUITY AGILE THERAPEUTICS INC AGRX EQUITY AGILENT TECHNOLOGIES INC A EQUITY AGILYSYS, INC. AGYS EQUITY AGIOS PHARMACEUTICALS INC AGIO EQUITY AGNC INVT CORP AGNC EQUITY AGNICO EAGLE MINES LTD AEM EQUITY AGREE REALTY CORP. ADC EQUITY AGRIUM INC AGU EQUITY AIMMUNE THERAPEUTICS INC AIMT EQUITY AIR LEASE CORP AL EQUITY AIR PRODUCTS & CHEMICALS INC APD EQUITY AIR TRANSPORT SERVICES GRP ATSG EQUITY AIRCASTLE LTD AYR EQUITY AIRMEDIA GROUP INC AMCN EQUITY AK STL HLDG CORP AKS EQUITY AKAMAI TECHNOLOGIES INC AKAM EQUITY AKEBIA THERAPEUTICS INC AKBA EQUITY AKERS BIOSCIENCES INC AKER EQUITY Page 2 Company_History ALAMO GROUP INC ALG EQUITY ALASKA AIR GROUP INC ALK EQUITY ALASKA COMMUNICATIONS SYS GR ALSK EQUITY ALBANY INTL CORP AIN EQUITY ALBANY MOLECULAR RESH INC AMRI EQUITY ALBEMARLE CORP ALB EQUITY ALBIREO PHARMA INC ALBO EQUITY ALCOA INC AA EQUITY ALCOBRA LTD ADHD EQUITY ALDER BIOPHARMACEUTICALS INC ALDR EQUITY ALDEYRA THERAPEUTICS INC ALDX EQUITY ALERE INC ALR EQUITY ALEXANDER & BALDWIN HOLDINGS INC. ALEX EQUITY ALEXANDERS INC ALX EQUITY ALEXANDRIA REAL ESTATE EQUITIES INC. ARE EQUITY ALEXION PHARMACEUTICALS INC ALXN EQUITY ALIBABA GROUP HLDG LTD BABA EQUITY ALICO INC ALCO EQUITY ALIGN TECHNOLOGY INC ALGN EQUITY ALIMERA SCIENCES INC. ALIM EQUITY ALKERMES PLC ALKS EQUITY ALLEGHANY CORP DEL Y EQUITY ALLEGHENY TECHNOLOGIES INC ATI EQUITY ALLEGIANCE BANCSHARES INC ABTX EQUITY ALLEGIANT TRAVEL CO ALGT EQUITY ALLEGION PUB LTD CO ALLE EQUITY ALLERGAN PLC AGN EQUITY ALLETE INCORPORATED ALE EQUITY ALLIANCE DATA SYSTEMS CORP ADS EQUITY ALLIANCE HEALTHCARE SRVCS IN AIQ EQUITY ALLIANCE HOLDINGS GP LP AHGP EQUITY ALLIANCE ONE INTL INC AOI EQUITY ALLIANCE RES PARTNER L P ARLP EQUITY ALLIANCEBERNSTEIN HOLDING LP AB EQUITY ALLIANT ENERGY CORPORATION LNT EQUITY ALLIED HEALTHCARE PRODS INC AHPI EQUITY ALLIED MOTION TECHNOLOGIES I AMOT EQUITY ALLIED WRLD ASSUR COM HLDG A AWH EQUITY ALLISON TRANSMISSION HLDGS I ALSN EQUITY ALLOT COMMUNICATIONS LTD ALLT EQUITY ALLSCRIPTS HEALTHCARE SOLUTN MDRX EQUITY ALLSTATE CORP ALL EQUITY ALLY FINL INC ALLY EQUITY ALMOST FAMILY INC AFAM EQUITY ALNYLAM PHARMACEUTICALS INC ALNY EQUITY ALON USA ENERGY INC ALJ EQUITY ALON USA PARTNERS LP ALDW EQUITY ALPHA & OMEGA SEMICONDUCTOR AOSL EQUITY ALPHA PRO TECH LTD APT EQUITY ALPHABET INC GOOGL EQUITY ALPHABET INC GOOG EQUITY ALPHATEC HOLDINGS INC ATEC EQUITY ALTERYX INC AYX EQUITY ALTISOURCE ASSET MGMT CORP AAMC EQUITY ALTISOURCE PORTFOLIO SOLNS S ASPS EQUITY Page 3 Company_History ALTISOURCE RESIDENTIAL CORP RESI EQUITY ALTRA INDL MOTION CORP AIMC EQUITY ALTRIA GROUP INC MO EQUITY ALUMINUM CORP CHINA LTD ACH EQUITY AMAG PHARMACEUTICALS INC AMAG EQUITY AMARIN CORP PLC AMRN EQUITY AMAZON COM INC AMZN EQUITY AMBARELLA INC AMBA EQUITY AMBER RD INC AMBR EQUITY AMC ENTMT HLDGS INC AMC EQUITY AMC NETWORKS INC AMCX EQUITY AMCON DISTRG CO DIT EQUITY AMDOCS LTD DOX EQUITY AMEDICA CORP AMDA EQUITY AMEDISYS INC AMED EQUITY AMERCO UHAL EQUITY AMEREN CORPORATION AEE EQUITY AMERESCO INC AMRC EQUITY AMERICA MOVIL SAB DE CV AMX EQUITY AMERICA MOVIL SAB DE CV AMOV EQUITY AMERICAN AIRLINES GROUP, INC. AAL EQUITY AMERICAN ASSETS TR INC AAT EQUITY AMERICAN AXLE & MFG HLDGS IN AXL EQUITY AMERICAN CAMPUS COMMUNITIES INC. ACC EQUITY AMERICAN EAGLE OUTFITTERS NE AEO EQUITY AMERICAN ELECTRIC POWER COMPANY, INCORPORATED AEP EQUITY AMERICAN EQTY INVT LIFE HLD AEL EQUITY AMERICAN EXPRESS CO AXP EQUITY AMERICAN FINANCIAL GROUP AFG EQUITY AMERICAN HOMES 4 RENT AMH EQUITY AMERICAN INTERNATIONAL GROUP, INC. AIG EQUITY AMERICAN MIDSTREAM PARTNERS AMID EQUITY AMERICAN NATIONAL INSURANCE COMPANY ANAT EQUITY AMERICAN NATL BANKSHARES INC AMNB EQUITY AMERICAN OUTDOOR BRANDS CORP AOBC EQUITY AMERICAN PUBLIC EDUCATION IN APEI EQUITY AMERICAN RAILCAR INDS INC ARII EQUITY AMERICAN REALTY INVESTORS INC ARL EQUITY AMERICAN RENAL ASSOCIATES HO ARA EQUITY AMERICAN SOFTWARE INC AMSWA EQUITY AMERICAN STATES WATER COMPANY AWR EQUITY AMERICAN SUPERCONDUCTOR CORP AMSC EQUITY AMERICAN TOWER CORP NEW AMT EQUITY AMERICAN VANGUARD CORP AVD EQUITY AMERICAN WOODMARK CORP AMWD EQUITY AMERICAN WTR WKS CO INC. AWK EQUITY AMERICAS CAR MART INC CRMT EQUITY AMERIGAS PARTNERS L P APU EQUITY AMERIPRISE FINL INC AMP EQUITY AMERIS BANCORP ABCB EQUITY AMERISAFE INC AMSF EQUITY AMERISOURCEBERGEN CORP ABC EQUITY AMES NATL CORP ATLO EQUITY AMETEK INC. AME EQUITY AMGEN INC AMGN EQUITY Page 4 Company_History AMICUS THERAPEUTICS INC FOLD EQUITY AMIRA NATURE FOODS LTD ANFI EQUITY AMKOR TECHNOLOGY INC AMKR EQUITY AMN HEALTHCARE SERVICES INC AMN EQUITY AMPCO‐PITTSBURGH CORP AP EQUITY AMPHASTAR PHARMACEUTICALS IN AMPH EQUITY AMPHENOL CORP. APH EQUITY AMREP CORP. AXR EQUITY AMTRUST FINL SVCS INC AFSI EQUITY AMYRIS INC AMRS EQUITY ANADARKO PETE CORP APC EQUITY ANALOG DEVICES INC ADI EQUITY ANALOGIC CORP ALOG EQUITY ANDERSONS INC ANDE EQUITY ANGIES LIST INC ANGI EQUITY ANGIODYNAMICS INC ANGO EQUITY ANGLOGOLD ASHANTI LTD AU EQUITY ANHEUSER‐BUSH INBEV SA BUD EQUITY ANI PHARMACEUTICALS INC ANIP EQUITY ANIKA THERAPEUTICS INC ANIK EQUITY ANIXTER INTL INC AXE EQUITY ANNALY CAP MGMT INC NLYPA EQUITY ANNALY CAPITAL MANAGEMENT INC NLY EQUITY ANSYS INC ANSS EQUITY ANTERO MIDSTREAM PARTNERS LP AM EQUITY ANTERO RES CORP AR EQUITY ANTHEM INC ANTM EQUITY ANTHERA PHARMACEUTICALS INC ANTH EQUITY ANWORTH MORTGAGE ASSET CORP ANH EQUITY AON CORPORATION PLC AON EQUITY AOXIN TIANLI GROUP INC ABAC EQUITY APACHE CORP APA EQUITY APARTMENT INVESTEMENT & MANAGEMENT CO AIV EQUITY APOGEE ENTERPRISES INC APOG EQUITY APOLLO COML REAL EST FIN INC ARI EQUITY APOLLO GLOBAL MGMT LLC APO EQUITY APPFOLIO INC APPF EQUITY APPLE HOSPITALITY REIT INC APLE EQUITY APPLE INC AAPL EQUITY APPLIED GENETIC TECHNOL CORP AGTC EQUITY APPLIED INDUSTRIAL TECHNOLOGIES AIT EQUITY APPLIED MATERIALS INC AMAT EQUITY APPLIED OPTOELECTRONICS INC AAOI EQUITY APPROACH RESOURCES INC AREX EQUITY APRICUS BIOSCIENCES INC APRI EQUITY APTARGROUP INC ATR EQUITY APTEVO THERAPEUTICS INC APVO EQUITY AQUA AMERICA INCORPORATED WTR EQUITY AQUA METALS INC AQMS EQUITY AQUINOX PHARMACEUTICALS INC AQXP EQUITY ARALEZ PHARMACEUTICALS INC ARLZ EQUITY ARAMARK ARMK EQUITY ARATANA THERAPEUTICS INC PETX EQUITY ARBOR REALTY TRUST INC ABR EQUITY ARC DOCUMENT SOLUTIONS INC ARC EQUITY Page 5 Company_History ARC LOGISTICS PARTNERS LP ARCX EQUITY ARCA BIOPHARMA INC ABIO EQUITY ARCADIA BIOSCIENCES INC RKDA EQUITY ARCBEST CORP ARCB EQUITY ARCH CAP GROUP LTD ACGL EQUITY ARCHER DANIELS MIDLAND CO ADM EQUITY ARCHROCK INC AROC EQUITY ARCHROCK PARTNERS L P APLP EQUITY ARCONIC INC ARNC EQUITY ARCOS DORADOS HOLDINGS INC ARCO EQUITY ARDAGH GROUP S A ARD EQUITY ARDELYX INC ARDX EQUITY ARENA PHARMACEUTICALS INC ARNA EQUITY ARES COML REAL ESTATE CORP ACRE EQUITY ARES MGMT L P ARES EQUITY ARGO GROUP INTL HLDGS LTD AGII EQUITY ARGOS THERAPEUTICS INC ARGS EQUITY ARK RESTAURANTS CORP ARKR EQUITY ARLINGTON ASSET INVT CORP AI EQUITY ARMADA HOFFLER PPTYS INC AHH EQUITY ARMSTRONG WORLD INDS INC NEW AWI EQUITY ARQULE INC ARQL EQUITY ARRAY BIOPHARMA INC ARRY EQUITY ARRIS INTL INC ARRS EQUITY ARROW ELECTRONICS INC ARW EQUITY ARROW FINANCIAL CORPORATION AROW EQUITY ARTESIAN RESOURCES CORP ARTNA EQUITY ARTISAN PARTNERS ASSET MGMT APAM EQUITY ASBURY AUTOMOTIVE GROUP INC ABG EQUITY ASCENA RETAIL GROUP INC ASNA EQUITY ASCENDIS PHARMA A S ASND EQUITY ASHFORD HOSPITALITY PRIME IN AHP EQUITY ASHFORD HOSPITALITY TRUST INC AHT EQUITY ASHFORD INC AINC EQUITY ASHLAND INC.
Load more

Recommended publications
  • By in Vivo's Biopharma, Medtech and Diagnostics Teams
    invivo.pharmaintelligence.informa.com JANUARY 2018 Invol. 36 ❚ no. 01 Vivopharma intelligence ❚ informa 2018 OUTLOOK By In Vivo’s Biopharma, Medtech and Diagnostics Teams PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ In Vivo Pharma intelligence | January 2018 BIOPHARMA MEDTECH 2018 DIAGNOSTICS OUTLOOK 12 22 28 Biopharma 2018: Medtech 2018: Diagnostics 2018: Is There Still A Place For Pharma The Place For Innovation Steady Progress And In The New Health Care As Value-based Health Care The Big Get Bigger Economy? Gains Momentum MARK RATNER WILLIAM LOONEY ASHLEY YEO If the beginning of 2017 was marked 2018 will be a time of transition in health 2017 was a watershed year in many by doubts around whether and how care, when biopharma’s counterparts respects, politically, economically the FDA would act with respect to in adjacent industry segments scale up and commercially for many players complex diagnostics, we enter 2018 in a radical redesign of their traditional in the medtech field. Where will the feeling that slow-moving vessel may business models. Biopharma is not opportunities lie in 2018? Will finally be turning. moving as quickly, and it confronts a breakthrough medtech innovation still strategic dilemma on how to address the have a place among providers often prospect of a much more powerful set of riding on fumes when it comes to 36 rivals in the ongoing battle to own the budgets, and is it all as bad as some patient experience in medicine. would make out? Thirty-five Years Covering Health Care: The More Things Change… 30 PETER CHARLISH A Virtuous Cycle: What The The health care industry has come a Immuno-Oncology Revolution long way in the past 35 years, although Means For Other Disease Areas in some areas very little has changed.
    [Show full text]
  • February 11-12, 2013 the Waldorf Astoria New York
    February 11-12, 2013 The Waldorf Astoria New York 15th ANNU AL EVENT Now in its fifteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. Reasons Top 10 to attend 1 Present your company story to an audience of targeted investors. 2 Hear the Washington perspective on the Affordable Care Act, debt ceiling, and other timely policy developments affecting the industry. 3 Evaluate fresh investment opportunities including compatible, complementary and competitive companies. 4 Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables. 5 Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013. 6 Gain access to BIO’s 1x1 Partnering System for scouting potential deal partners and optimizing your time at the event. 7 Access presentations from more than 140 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences. 8 Get the pulse on the current and proposed investment trends in biotechnology. 9 Network with peers, investors and potential partners attending the conference. 10 It’s the first NYC biotech conference of the year, kicking off a week of key industry events that you don’t want to miss.
    [Show full text]
  • CDER – Redi: Focus on CGMP & FDA Inspections – Participant List
    FDA – CDER – RedI: Focus on CGMP & FDA Inspections – Participant List These participants granted permission to share their contact information Eileen Zhou Michael Channing A B M Mahfuz ul Alam Research Associate Group Chief - Positron Emission General Manager, Quality Operations Neuralstem Tomography Department ACI HealthCare Limited Germantown, MD, United States NIH Dhaka, Non-US, Bangladesh [email protected] Bethesda, MD, United States [email protected] [email protected] Abe Wong ABHIJEET GUJAR Adam Ebbinghouse CCO Chief Operating Officer QC Associate Gmpsigma SETHU KP Pharmaceutical Technology, Inc. Seattle, WA, United States Porvorim Goa, Non-US, India Bloomington, IN, United States [email protected] [email protected] [email protected] Adil Gatrad Adiseshu Modugula Aditiben Patel Director, Quality Systems RA Regulatory Specialist Actavis MSN USAMMDA Parsippany, NJ, United States Hyderabad, Non-US, India Frederick, MD, United States [email protected] [email protected] [email protected] Adriana de la Cruz ahsanul haque Aimee Gogarty Manager CSO Quality Coordinator Laboratorios Pisa SA de CV FDA Mallinckrodt Jalisco, Non-US, Mexico silver spring, MD, United States Port Allen, LA, United States [email protected] [email protected] [email protected] Aislyn Fronzak Ajay Deshmukh Ajay Khedkar QC Manager QA manager Regulatory Affair PL Developments Ingenus Pharmaceutical Umedica Laboratories Pvt Ltd Clinton, SC, United States Navi mumbai, Non-US, India Mumbai, Non-US, India [email protected]
    [Show full text]
  • The Weekly Shot Biotech Issue a Weekly Summary of Healthcare Industry Valuation and Near-Term Catalysts June 17, 2010
    Small Cap The Weekly Shot Biotech Issue June 17, 2010 A weekly summary of healthcare industry valuation and near-term catalysts The Weekly Shot: Overview and Comment - Small Cap Biotechnology Next week's sector highlights include LGND’s Thursday analyst event at the Eventi - Pharmaceuticals and Large Cap Biotech Hotel in NYC. The company on 6/15 announced updated 2010 revenue guidance of approx $25M, op ex of approx $30M, and expects to finish the year with $30M - Generics and Specialty Pharmaceuticals in cash (vs approx $43M as of 1Q10). Management will likely focus on partner GSK’s progress with add’l trials of Promacta (for ITP), which could potentially expand the drug’s label to Hep C, AML, and MDS (LGND receives <10% royalty from GSK). Investors should focus on pipeline plans following LGND’s opportunistic 2008/09 M&A activity. Key pipeline programs include LGD-4033 (ph.I, SARM candidate from PCOP) and RG7348, partnered with Roche (ph.I, Hep C candidate from MBRX). We do not expect major data announcements at the event. FDA’s Pediatric Drugs Advisory Committee will meet Monday to discuss pediatric safety reviews of multiple approved drugs, including Kogenate, Casodex, Apidra, NovoLog, Arimidex, Desmopressin, Prevacid, Nexium, Aciphex, Priolex, OraVerse, Zemuron, and Suprane . While important from a public safety perspective, we do not anticipate regulatory activity to be announced. Brian Lian, Ph.D. Small caps biotechs rebounded mid-week as elevated volatility continued across 212.500.6646 [email protected] the broader market. Investors are struggling to balance economic data supporting a modest recovery against concerns on EU debt loads, financial reform legislation, and aggressive govt rhetoric on BP’s oil spill.
    [Show full text]
  • CURRICULUM VITAE MARK DAVID SANCHEZ, MD, FACOG 2454 Mcmullen Booth Rd., Suite 601 Phone: (727) 796­7705
    CURRICULUM VITAE MARK DAVID SANCHEZ, MD, FACOG 2454 McMullen Booth Rd., Suite 601 Phone: (727) 796­7705 CURRENT POSITIONS Reproductive Endocrinologist IVF Medical Director Florida Fertility Institute Clearwater, Florida Associate Medical Director and Investigator Women's Medical Research Group, LLC Clearwater, Florida Associate Medical Director and Investigator Florida Clinical Research Group Clearwater, Florida Department Chair Obstetrics and Gynecology Bayfront Medical Center St. Petersburg, Florida BIRTH DATE and PLACE March 25, 1969, Indianapolis, IN EDUCATION and TRAINING 1999­2002 Fellowship in Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology University of South Florida Tampa, Florida 1995­1999 Obstetrics and Gynecology Residency Department of Obstetrics and Gynecology Bayfront Medical Center St. Petersburg, Florida 1991­1995 Doctor of Medicine University of Florida College of Medicine Gainesville, Florida 1989­1991 Bachelor of Science Major: Biology Minor: History University of South Florida Tampa, Florida WORK EXPERIENCE 2002­2014 Reproductive Endocrinologist IVF Medical Director Florida Fertility Institute Clearwater, Florida 2003­2014 Associate Medical Director and Investigator Women's Medical Research Group, LLC Clearwater, Florida 2003­2014 Associate Medical Director and Investigator Florida Clinical Research Group Clearwater, Florida LICENSES, CERTIFICATIONS, AND EXAMINATIONS 1996 Florida Medical License (Active) 2005 Board Certified Reproductive Endocrinology and Infertility 2004 Board Certified
    [Show full text]
  • Colleges Can Subscribe to the B.M.7
    540 30 August 1969 News and Notes WHITTET, Craig Dunain Hospital, Inverness, epi- of the Brompton Hospital), Fulham Road, SOCIETY OF APOTHECARIES OF demioldgy of alcoholism in the Highlands and Islands, £7,500 over three years, from funds pro- London S.W.3, on Fridays at 5 p.m. from LONDON vided by the Distillers Company Limited for 3 October to 5 December inclusive. L.M.S.S.A.-S. G. Taktak, A. M. Hasan, H. T. research into alcoholism. Abu-Zahra, K. G. A. M. Ghattas, L. S. Nakhla, Br Med J: first published as 10.1136/bmj.3.5669.540 on 30 August 1969. Downloaded from B. A. K. Al-Kazzaz, M. Amanullah, F. R. Akrawy, IX Congris National des Midecins de M. A. Shanif, W M. Umrani, A. F. M. S. Rahman, Strike by Ambulance Men M. M. Abdel Rahman, W. F. Abadir, J. Y. Hallac, Ambulance drivers withdrew services from Centres de Sante.-16-18 October. Details A. F M. Shamsul Alam, M. Impallomeni, D. B. from Secretariat, 3 rue de Stockholm, Albuquerque, 0. E. F. M. Fadl, M. Habboushe, 25 of London's 76 ambulance stations earlier G. Gordon, G. R. Tadross, F. S. Mina, M. A. B, this week, and the Federation of Ambulance Paris 8. El-Gothamy, A. A. Shihata, S. D. Sarkar, A. M. H Aboul-Ata, E. F. Sayegh, J. K. S. Wee, S. S. Personnel claimed that the strike action Michail, M. H. Rahman, A. R. I. Ahmed, Z. would be extended if its claims were not met. Symposium on Patient Monitoring.-24 Husain.
    [Show full text]
  • FIDELITY SELECT PORTFOLIOS Form N-Q Filed 2017-01-27
    SECURITIES AND EXCHANGE COMMISSION FORM N-Q Quarterly schedule of portfolio holdings of registered management investment company filed on Form N-Q Filing Date: 2017-01-27 | Period of Report: 2016-11-30 SEC Accession No. 0001379491-17-000373 (HTML Version on secdatabase.com) FILER FIDELITY SELECT PORTFOLIOS Mailing Address Business Address 245 SUMMER STREET 245 SUMMER STREET CIK:320351| IRS No.: 000000000 | State of Incorp.:MA | Fiscal Year End: 0228 BOSTON MA 02210 BOSTON MA 02210 Type: N-Q | Act: 40 | File No.: 811-03114 | Film No.: 17551660 617-563-7000 Copyright © 2017 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-3114 Fidelity Select Portfolios (Exact name of registrant as specified in charter) 245 Summer St., Boston, Massachusetts 02210 (Address of principal executive offices) (Zip code) Marc Bryant, Secretary 245 Summer St. Boston, Massachusetts 02210 (Name and address of agent for service) Registrant's telephone number, including area code: 617-563-7000 Date of fiscal year end: February 28 Date of reporting period: November 30, 2016 Item 1. Schedule of Investments Quarterly Holdings Report for Fidelity® Select Portfolios® Semiconductors Portfolio (formerly Electronics Portfolio) November 30, 2016 ELE-QTLY-0117 1.810682.112 Copyright © 2013 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Investments November 30, 2016 (Unaudited) Showing Percentage of Net Assets Common Stocks - 95.3% Shares Value Biotechnology - 0.0% Biotechnology - 0.0% Arrowhead Pharmaceuticals, Inc.
    [Show full text]
  • Pharmaceuticals, Medical Devices and Biologics Regulatory and Policy Bulletin
    Antitrust Connection Spring 2009 To: Our Clients and Friends October 30, 2009 Pharmaceuticals, Medical Devices and Biologics Regulatory and Policy Bulletin Top News House Reform Bill Lowers Device Tax, But No Exception for Small Companies The updated House health care reform bill reduces the device industry excise tax to $20 billion (compared to $40 billion in the Senate bill), but includes no exceptions for small companies. Senators Introduce Bill to Eliminate Write-Off for Drug Marketing Costs Senators Al Franken (D-Minn.), Sherrod Brown (D-Ohio), and Sheldon Whitehouse (D- R.I.), have introduced S.1763, a bill that would eliminate the tax write-off for prescription drug marketing costs, as a means to "restore lost revenue" to the federal government. The bill covers direct-to-consumer advertising in any media and "any activity designed to promote the use of a prescription pharmaceutical directed to providers or others who may make decisions about the use of prescription pharmaceuticals (including the provision of product samples, free trials and starter kits)." U.S.-Japan Pilot Project In Pre-Market Collaboration to Begin Soon The FDA and its Japanese counterpart will soon name the two devices that they will use as part of a pilot project in which the countries’ agencies will collaborate on clinical trial protocol development and pre-market review of medical devices. The pilot is part of the of the Harmonization by Doing (HBD) initiative. Pfizer, GSK and Bayer accept Ecuador’s plan to break patents Pfizer, GlaxoSmithKline (GSK) and Bayer have expressed their support for the government of Ecuador’s decision to sidestep patents on more than 2,000 drugs, enabling the country to produce them locally or import them as “generics.” The move is similar to that seen in countries including Brazil and Thailand, who have taken similar action in an effort to reduce drug prices.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-39555 GREENWICH LIFESCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 20-5473709 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3992 Bluebonnet Dr., Building 14, Stafford, Texas 77477 77477 (Address of principal executive offices) (Zip Code) (832) 819-3232 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock, $0.001 par value The NASDAQ Capital Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No [X] Indicate by check if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [ ] No [X] Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • BIODEL INC. (Exact Name of Registrant As Specified in Its Charter) Delaware 90-0136863 (State Or Other Jurisdiction of (I.R.S
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K/A (Amendment No. 1) (Mark One) R ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33451 BIODEL INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 90-0136863 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) 100 Saw Mill Road 06810 Danbury, CT (Zip Code) (Address of Principal Executive Offices) Registrant’s telephone number, including area code (203) 796-5000 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, par value $0.01 per share The NASDAQ Capital Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No R Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No R Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days Yes R No o Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
    [Show full text]
  • Scottish Industrial History Vol 20 2000
    SCOTTISH INDUSTRIAL HISTORY Scotl21nd Business Archives Council of Scotland Scottish Charity Number SCO 02565 Volume20 The Business Archives Council of Scotland is grateful for the generous support given to this edition of Scottish Industrial History by United Distillers & Vintners SCOTTISH INDUSTRIAL HISTORY Volume20 B·A·C Scotl21nel Business Archives Council of Scotland Scorrish Choriry Number SCO 02565 Scottish Industrial History is published by the Business Archives Council of Scotland and covers all aspects of Scotland's industrial and commercial past on a local, regional and trans-national basis. Articles for future publication should be submitted to Simon Bennett, Honorary Editor, Scottish Industrial History, Archives & Business Records Centre, 77-87 Dumbarton Road, University of Glasgow Gll 6PE. Authors should apply for notes for contributors in the first instance. Back issues of Scottish Industrial History can be purchased and a list of titles of published articles can be obtained from the Honorary Editor or BACS web-site. Web-site: http://www.archives.gla.ac.uklbacs/default.html The views expressed in the journal are not necessarily those of the Business Archives Council of Scotland or those of the Honorary Editor. © 2000 Business Archives Council of Scotland and contributors. Cover illustrations Front: Advertisement Punch 1925- Johnnie Walker whisky [UDV archive] Back: Still room, Dalwhinnie Distillery 1904 [UDV archive] Printed by Universities Design & Print, University of Strathclyde 'Whisky Galore ' An Investigation of Our National Drink This edition is dedicated to the late Joan Auld, Archivist of the University of Dundee Scottish Industrial History Volume20 CONTENTS Page Scotch on the Records 8 Dr. R.B.
    [Show full text]
  • Curriculum Vitae
    1 | P a g e CURRICULUM VITAE MARK DAVID SANCHEZ, MD, FACOG 2454 McMullen Booth Rd., Suite 601 Phone: (727) 796-7705 E-mail: CURRENT POSITIONS Reproductive Endocrinologist IVF Medical Director Florida Fertility Institute Clearwater, Florida Associate Medical Director and Investigator Women's Medical Research Group, LLC Clearwater, Florida Associate Medical Director and Investigator Florida Clinical Research Group Clearwater, Florida Department Chair Obstetrics and Gynecology Bayfront Medical Center St. Petersburg, Florida BIRTH DATE and PLACE March 25, 1969, Indianapolis, IN EDUCATION and TRAINING 1999-2002 Fellowship in Reproductive Endocrinology and Infertility 2 | P a g e Department of Obstetrics and Gynecology University of South Florida Tampa, Florida 1995-1999 Obstetrics and Gynecology Residency Department of Obstetrics and Gynecology Bayfront Medical Center St. Petersburg, Florida 1991-1995 Doctor of Medicine University of Florida College of Medicine Gainesville, Florida 1989-1991 Bachelor of Science Major: Biology Minor: History University of South Florida Tampa, Florida WORK EXPERIENCE 2002-2014 Reproductive Endocrinologist IVF Medical Director Florida Fertility Institute Clearwater, Florida 2003-2014 Associate Medical Director and Investigator Women's Medical Research Group, LLC Clearwater, Florida 2003-2014 Associate Medical Director and Investigator Florida Clinical Research Group Clearwater, Florida 3 | P a g e LICENSES, CERTIFICATIONS, AND EXAMINATIONS 1996 Florida Medical License (Active) 2005 Board Certified Reproductive
    [Show full text]